Immune checkpoint inhibitors (ICIs), PARP inhibitors, VEGF inhibitors, kinase inhibitors, and chemotherapy are all being used in various combinations for the treatment of endometrial and ovarian cancers. As these new combinations seek to further improve and enhance the efficacy of treatment, the risk of AEs increases. During this informational podcast, Dr. Richard Penson and Ms. Jennifer Filipi will educate clinicians on the prevention, mitigation, and management of AEs that arise from these new combination regimens.